AZTR Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (17 mai 2024 @ 21:59):

Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases...

Stats
Dagens volum	11.71M
Gjennomsnittsvolum	927 342
Markedsverdi	5.24M
EPS	$0 ( 2024-03-12 )
Neste inntjeningsdato	( $0 ) 2024-06-21
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.100
ATR14	$0.00200 (1.10%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-29	Staskey Norm	Buy	47 600	Common Stock
2024-02-13	Whitfill Travis	Buy	15 000	Common Stock
2024-02-13	Staskey Norm	Buy	3 300	Common Stock
2024-02-13	Salva Francisco D.	Buy	333 300	Common Stock
2023-09-08	Staskey Norm	Buy	10 000	Stock Options (Right To Buy)

INSIDER POWER
44.35
Last 69 transactions
Buy: 15 407 806 \| Sell: 6 059 394

Volum Korrelasjon

Lang: -0.15 (neutral)

Kort: -0.36 (neutral)

Signal:(41.701) Neutral

Azitra, Inc. Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Azitra, Inc. Korrelasjon - Valuta/Råvare

-0.62
( weak negative )

-0.70
( moderate negative )

0.00
( neutral )

0.49
( neutral )

Azitra, Inc. Økonomi

Annual	2023
Omsetning:	$686 000
Bruttogevinst:	$686 000 (100.00 %)
EPS:	$-1.630

FY	2023
Omsetning:	$686 000
Bruttogevinst:	$686 000 (100.00 %)
EPS:	$-1.630

FY	2022
Omsetning:	$284 000
Bruttogevinst:	$284 000 (100.00 %)
EPS:	$-0.880

Financial Reports:

No articles found.

Azitra, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Azitra, Inc.

Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.